29 June 2022 in Science Translational Medicine
Carbon monoxide (CO) has long been considered a toxic gas but is now a recognized bioactive gasotransmitter with potent immunomodulatory effects. Although inhaled CO is currently under investigation for use in patients with lung disease, this mode of administration can present clinical challenges. The capacity to deliver CO directly and safely to the gastrointestinal (GI) tract could transform the management of diseases affecting the GI mucosa such as inflammatory bowel disease or radiation injury. To address this unmet need, inspired by molecular gastronomy techniques, we have developed a family of gas-entrapping materials (GEMs) for delivery of CO to the GI tract. We show highly tunable and potent delivery of CO, achieving clinically relevant CO concentrations in vivo in rodent and swine models. To support the potential range of applications of foam GEMs, we evaluated the system in three distinct disease models. We show that a GEM containing CO dose-dependently reduced acetaminophen-induced hepatocellular injury, dampened colitis-associated inflammation and oxidative tissue injury, and mitigated radiation-induced gut epithelial damage in rodents. Collectively, foam GEMs have potential paradigm-shifting implications for the safe therapeutic use of CO across a range of indications.
1 October 2021 in Advanced Drug Delivery Reviews
28 March 2025 in American Journal of Clinical Dermatology
5 March 2026 in British Journal of Dermatology
Background: Pyoderma gangrenosum (PG) is a rare, painful neutrophilic dermatosis with a profound impact on patient quality of life. Its management is hindered by a lack of approved therapies, limited clinical trials, and low-quality evidence. The rarity of the disease and funding constraints have impeded research progress and the development of standardized outcome measures. Patient data registries offer a promising solution to these challenges, providing essential infrastructure to improve the generation of evidence and clinical care. Objectives: To develop a consensus-based minimum dataset for an international treatment effectiveness registry for PG, informed by real-world clinical data. Methods: An initial list of candidate domain items was generated from a systematic literature review conducted according to a previously published protocol. An international, multistakeholder panel of 45 participants – including patients with PG, clinicians, researchers, methodologists and industry representatives – was convened from 97 invited experts. Through three rounds of modified Delphi surveys and a virtual consensus meeting, items were ranked using predefined criteria: ‘consensus in’ (≥ 70% scoring 7–9 and ≤ 15% scoring 1–3), ‘consensus out’ (≥ 70% scoring 1–3 and ≤ 15% scoring 7–9) and ‘no consensus’. A final verification survey confirmed inclusion if < 30% of participants voted ‘no’. Results: All 45 stakeholders completed all three Delphi rounds (0% dropout). Thirty-four (76%) participated in the consensus meeting, and 42 (93%) completed the final verification survey. Of 143 initial items across 24 domains, 118 items across 26 domains achieved consensus for inclusion in the minimum dataset. Conclusions: This international consensus establishes a standardized framework for collecting real-world data on PG. The resulting registry will serve as a critical resource for evaluating treatment effectiveness, understanding disease progression, and improving patient outcomes. It will also support future clinical trials, guideline development, quality improvement initiatives, and global patient recruitment efforts.
9 November 2024 in Australasian Journal of Dermatology
22 September 2025 in American Journal of Clinical Dermatology